# Sabra Health Care REIT, Inc.: financial statements, quarterly

SBRA · Nasdaq · CIK 1492298 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sbra.md) · [Financials](/companies/sbra/financials.md) · [Filings](/companies/sbra/filings.md) · [Insiders](/companies/sbra/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sbra/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [59.7](/filings/0001492298-24-000031.md) | [61.3 d](/filings/0001492298-26-000008.md) | [66.0](/filings/0001492298-25-000016.md) | [67.9](/filings/0001492298-25-000031.md) | [73.7](/filings/0001492298-25-000039.md) | [76.9 d](/filings/0001492298-26-000008.md) | [77.4](/filings/0001492298-26-000012.md) | [79.0](/filings/0001492298-26-000028.md) | [92.0](/filings/0001492298-25-000039.md) | [108 d](/filings/0001492298-26-000008.md) | [117](/filings/0001492298-26-000012.md) | [129](/filings/0001492298-26-000028.md) |
| Income tax | $m | [0.5](/filings/0001492298-24-000031.md) | [0.5 d](/filings/0001492298-26-000008.md) | [0.5](/filings/0001492298-25-000016.md) | [0.4](/filings/0001492298-25-000031.md) | [(0.3)](/filings/0001492298-25-000039.md) | [0.4 d](/filings/0001492298-26-000008.md) | [0.4](/filings/0001492298-26-000012.md) | [0.5](/filings/0001492298-26-000028.md) | [0.4](/filings/0001492298-25-000039.md) | [0.5 d](/filings/0001492298-26-000008.md) | [0.5](/filings/0001492298-26-000012.md) | [0.7](/filings/0001492298-26-000028.md) |
| Net income | $m | [(15.1)](/filings/0001492298-24-000031.md) | [17.2 d](/filings/0001492298-26-000008.md) | [26.3](/filings/0001492298-25-000016.md) | [24.0](/filings/0001492298-25-000031.md) | [29.8](/filings/0001492298-25-000039.md) | [46.7 d](/filings/0001492298-26-000008.md) | [40.3](/filings/0001492298-26-000012.md) | [65.5](/filings/0001492298-26-000028.md) | [22.5](/filings/0001492298-25-000039.md) | [27.2 d](/filings/0001492298-26-000008.md) | [40.9](/filings/0001492298-26-000012.md) | [(25.2)](/filings/0001492298-26-000028.md) |
| Diluted EPS | $ per share | [(0.07)](/filings/0001492298-24-000031.md) | not reported | [0.11](/filings/0001492298-25-000016.md) | [0.10](/filings/0001492298-25-000031.md) | [0.13](/filings/0001492298-25-000039.md) | not reported | [0.17](/filings/0001492298-26-000012.md) | [0.27](/filings/0001492298-26-000028.md) | [0.09](/filings/0001492298-25-000039.md) | not reported | [0.16](/filings/0001492298-26-000012.md) | [(0.10)](/filings/0001492298-26-000028.md) |
| Basic EPS | $ per share | [(0.07)](/filings/0001492298-24-000031.md) | not reported | [0.11](/filings/0001492298-25-000016.md) | [0.10](/filings/0001492298-25-000031.md) | [0.13](/filings/0001492298-25-000039.md) | not reported | [0.17](/filings/0001492298-26-000012.md) | [0.28](/filings/0001492298-26-000028.md) | [0.09](/filings/0001492298-25-000039.md) | not reported | [0.16](/filings/0001492298-26-000012.md) | [(0.10)](/filings/0001492298-26-000028.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.3](/filings/0001492298-23-000025.md) | [41.3](/filings/0001492298-25-000008.md) | [59.9](/filings/0001492298-24-000014.md) | [36.4](/filings/0001492298-24-000025.md) | [63.0](/filings/0001492298-24-000031.md) | [60.5](/filings/0001492298-26-000008.md) | [22.7](/filings/0001492298-25-000016.md) | [95.2](/filings/0001492298-25-000031.md) | [201](/filings/0001492298-25-000039.md) | [71.5](/filings/0001492298-26-000028.md) | [117](/filings/0001492298-26-000012.md) | [232](/filings/0001492298-26-000028.md) |
| Total assets | $m | [5,381](/filings/0001492298-23-000025.md) | [5,386](/filings/0001492298-25-000008.md) | [5,374](/filings/0001492298-24-000014.md) | [5,351](/filings/0001492298-24-000025.md) | [5,366](/filings/0001492298-24-000031.md) | [5,304](/filings/0001492298-26-000008.md) | [5,233](/filings/0001492298-25-000016.md) | [5,328](/filings/0001492298-25-000031.md) | [5,565](/filings/0001492298-25-000039.md) | [5,493](/filings/0001492298-26-000028.md) | [5,591](/filings/0001492298-26-000012.md) | [5,513](/filings/0001492298-26-000028.md) |
| Total liabilities | $m | [2,512](/filings/0001492298-23-000025.md) | [2,584](/filings/0001492298-25-000008.md) | [2,607](/filings/0001492298-24-000014.md) | [2,589](/filings/0001492298-24-000025.md) | [2,621](/filings/0001492298-24-000031.md) | [2,562](/filings/0001492298-26-000008.md) | [2,531](/filings/0001492298-25-000016.md) | [2,617](/filings/0001492298-25-000031.md) | [2,738](/filings/0001492298-25-000039.md) | [2,670](/filings/0001492298-26-000028.md) | [2,803](/filings/0001492298-26-000012.md) | [2,760](/filings/0001492298-26-000028.md) |
| Long-term debt | $m | [2,349](/filings/0001492298-23-000025.md) | [2,414](/filings/0001492298-24-000008.md) | [2,463](/filings/0001492298-24-000014.md) | [2,447](/filings/0001492298-24-000025.md) | [2,470](/filings/0001492298-24-000031.md) | [2,418](/filings/0001492298-25-000008.md) | [2,394](/filings/0001492298-25-000016.md) | [2,480](/filings/0001492298-25-000031.md) | [2,591](/filings/0001492298-25-000039.md) | [2,529](/filings/0001492298-26-000008.md) | [2,665](/filings/0001492298-26-000012.md) | [2,626](/filings/0001492298-26-000028.md) |
| Shareholders' equity | $m | [2,869](/filings/0001492298-24-000031.md) | [2,803](/filings/0001492298-25-000031.md) | [2,767](/filings/0001492298-25-000031.md) | [2,762](/filings/0001492298-25-000031.md) | [2,745](/filings/0001492298-24-000031.md) | [2,741](/filings/0001492298-26-000008.md) | [2,702](/filings/0001492298-25-000031.md) | [2,711](/filings/0001492298-25-000031.md) | [2,825](/filings/0001492298-25-000039.md) | [2,822](/filings/0001492298-26-000028.md) | [2,786](/filings/0001492298-26-000012.md) | [2,751](/filings/0001492298-26-000028.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [83.2 d](/filings/0001492298-24-000031.md) | [78.7 d](/filings/0001492298-26-000008.md) | [52.8](/filings/0001492298-25-000016.md) | [80.1 d](/filings/0001492298-25-000031.md) | [97.7 d](/filings/0001492298-25-000039.md) | [80.0 d](/filings/0001492298-26-000008.md) | [80.3](/filings/0001492298-26-000012.md) | [81.0 d](/filings/0001492298-26-000028.md) | [100.0 d](/filings/0001492298-25-000039.md) | [87.4 d](/filings/0001492298-26-000008.md) | [98.4](/filings/0001492298-26-000012.md) | [85.8 d](/filings/0001492298-26-000028.md) |
| Dividends paid | $m | [69.4 d](/filings/0001492298-24-000031.md) | [69.4 d](/filings/0001492298-26-000008.md) | [69.4](/filings/0001492298-25-000016.md) | [69.5 d](/filings/0001492298-25-000031.md) | [70.3 d](/filings/0001492298-25-000039.md) | [71.0 d](/filings/0001492298-26-000008.md) | [71.4](/filings/0001492298-26-000012.md) | [71.4 d](/filings/0001492298-26-000028.md) | [71.9 d](/filings/0001492298-25-000039.md) | [74.8 d](/filings/0001492298-26-000008.md) | [75.7](/filings/0001492298-26-000012.md) | [75.7 d](/filings/0001492298-26-000028.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [231](/filings/0001492298-23-000025.md) | [231](/filings/0001492298-24-000014.md) | [232](/filings/0001492298-24-000025.md) | [231](/filings/0001492298-24-000031.md) | [233](/filings/0001492298-25-000016.md) | [234](/filings/0001492298-25-000031.md) | [237](/filings/0001492298-25-000039.md) | [240](/filings/0001492298-26-000012.md) | [241](/filings/0001492298-26-000028.md) | [244](/filings/0001492298-25-000039.md) | [256](/filings/0001492298-26-000012.md) | [252](/filings/0001492298-26-000028.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 255,462,756 at 2026-07-27, from the cover of the [10-Q filed 2026-08-03](/filings/0001492298-26-000028.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.